Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT)

Next Previous
Trial Profile

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms BENEFIT-EXT
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 08 Jun 2022 Results assessing long-term allograft function between belatacept-based regimens and tacrolimus-based regimen up to five years from two clinical studies: BENEFIT and BENEFIT EXT presented at the 2022 American Transplant Congress
    • 08 Jun 2022 Results assessing the performances of the iBox system to capture this hemodynamic effect to predict long term graft survival in patients under a CNI free regimen in two studies (BENEFIT & BENEFIT EXT) presented at the 2022 American Transplant Congress.
    • 24 Dec 2019 Results of post-hoc analysis of patient-reported outcomes from the Phase III belatacept trials investigating the interrelationship between trajectories of HRQoL, symptom experience, and allograft outcomes published in the American Journal of Transplantation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top